[1] Trivedi P J, Hirschfield G M. Recent advances in clinical practice: epidemiology of autoimmune liver diseases[J]. Gut, 2021, 70(10): 1989-2003.
[2] Van Den Brand F F, Van Der Veen K S, De Boer Y S, et al. Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis[J]. Clin Gastroenterol Hepatol, 2019, 17(5): 940-947.e2.
[3] Singal A G, Kanwal F, Llovet J M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy[J]. Nature Reviews. Clin Oncol, 2023, 20(12): 864-884.
[4] Yan L J, Yao S Y, Meng G X, et al. Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis.[J]. Hepatol Int, 2021, 15(6): 1413-1420.
[5] Colapietro F, Maisonneuve P, Lytvyak E, et al. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis[J]. J Hepatol, 2023.
[6] Dave S, Park S, Murad M H, et al. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis[J]. Hepatology, 2021, 73(1): 68-78.
[7] Morgan R L, Baack B, Smith B D, et al. Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies[J]. Ann Intern Med, 2013, 158(5_Part_1): 329.
[8] Llovet J M, Pinyol R, Kelley R K, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma[J]. Nat Cancer, 2022, 3(4): 386-401.
[9] Choi J, Choi G H, Lee D, et al. Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country[J]. Liver Int,2019, 39(5): 985-994.
[10] Migita K, Watanabe Y, Jiuchi Y, et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study).[J]. Liver Int,2012, 32(5): 837-844.
[11] Tansel A, Katz L H, El-Serag H B, et al. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2017, 15(8): 1207-1217.e4.
[12] Hino-Arinaga T, Ide T, Kuromatsu R, et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1.[J]. J Gastroenterol, 2012, 47(5): 569-576.
[13] Yoshizawa K, Matsumoto A, Ichijo T, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis[J]. Hepatology, 2012, 56(2): 668-676.
[14] Valean S, Acalovschi M, Dumitrascu D L, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis - a systematic review of the literature published between 1989-2016.[J]. Med Pharm Rep,2019, 92(2): 99-105.
[15] Vaz N F, Margon J F, Moutinho B D, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis: prevalence and risk factors[J]. J Hepatol, 2020, 73: S465.
[16] Yeoman A D, Al-Chalabi T, Karani J B, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening[J]. Hepatology, 2008, 48(3): 863-870.
[17] Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study[J]. J Hepatol, 2014, 60(3): 612-617.
[18] Czaja A J. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.[J]. Dig Dis Sci, United States: 2013, 58(6): 1459-1476.
[19] De Luca-Johnson J, Wangensteen K J, Hanson J, et al. Natural History of Patients Presenting with Autoimmune Hepatitis and Coincident Nonalcoholic Fatty Liver Disease[J]. Dig Dis Sci, 2016, 61(9): 2710-2720.
[20] Takahashi A, Arinaga-Hino T, Ohira H, et al. Non-alcoholic fatty liver disease in patients with autoimmune hepatitis[J]. JGH Open, 2018, 2(2): 54-58.
[21] Zachou K, Azariadis K, Lytvyak E, et al. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease[J]. JHEP Rep, 2023, 5(8): 100778.
[22] Singal A G, Llovet J M, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78(6): 1922.
[23] Wang G, Tanaka A, Zhao H, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis[J]. Hepatol Int, 2021, 15(2): 223-257.
[24] European Association for the Study of the L. EASL Clinical Practice Guidelines: Autoimmune hepatitis[J]. J Hepatol, 2015, 63(4): 971-1004.
[25] Mack C L, Adams D, Assis D N, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. |
